Hoffmann-La Roche Company Description
Hoffmann-La Roche is the US prescription pharmaceuticals unit of Roche. The company develops, manufactures, and markets drugs to treat such life-threatening conditions as AIDS, cancer, and heart disease. Other product categories include central nervous system (CNS) disorders, organ transplant rejection, and skin conditions. Hoffmann-La Roche's products include influenza fighter Tamiflu, cancer drug Xeloda, HIV inhibitor Fuzeon (co-marketed with Trimeris), obesity drug Xenical, and hepatitis B and C therapy Pegasys. Hoffmann-La Roche's R&D is focused on oncology and metabolic, CNS, virology, inflammatory, respiratory, and autoimmune diseases.
View the Comprehensive Company Description for Hoffmann-La Roche
The Company Description provides a historical perspective of Hoffmann-La Roche's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Hoffmann-La Roche's evolution in the marketplace.
